Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara Linse

Showing results (271-280 of 285) with videos related to

Pageof 29
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|December 25, 2016
Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer's diseaseJohnny Habchi, Sean Chia, Ryan Limbocker, et al.
Nature Chemistry|May 9, 2018
Cholesterol catalyses Aβ42 aggregation through a heterogeneous nucleation pathway in the presence of lipid membranesJohnny Habchi, Sean Chia, Céline Galvagnion, et al.
Communications Biology|January 5, 2021
A dopamine metabolite stabilizes neurotoxic amyloid-β oligomersRodrigo Cataldi, Sean Chia, Katarina Pisani, et al.
Communications Biology|January 27, 2021
Publisher Correction: A dopamine metabolite stabilizes neurotoxic amyloid-β oligomersRodrigo Cataldi, Sean Chia, Katarina Pisani, et al.
ACS Nano|December 19, 2015
Microfluidic Diffusion Analysis of the Sizes and Interactions of Proteins under Native Solution ConditionsPaolo Arosio, Thomas Müller, Luke Rajah, et al.
Science Advances|March 3, 2016
An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Aβ42 aggregates linked with Alzheimer's diseaseJohnny Habchi, Paolo Arosio, Michele Perni, et al.
Nature Communications|August 17, 2024
α-Synuclein oligomers form by secondary nucleationCatherine K Xu, Georg Meisl, Ewa A Andrzejewska, et al.
Chemical Science|May 17, 2024
Molecular mechanism of α-synuclein aggregation on lipid membranes revealedAlexander J Dear, Xiangyu Teng, Sarah R Ball, et al.
Nature Structural & Molecular Biology|September 29, 2020
Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodiesSara Linse, Tom Scheidt, Katja Bernfur, et al.
Nature Communications|February 18, 2026
Structural defects in amyloid-β fibrils drive secondary nucleationJing Hu, Tom Scheidt, Dev Thacker, et al.
Pageof 29

Showing results (271-280 of 285) with videos related to

Sort By:
Pageof 29
Proceedings of the National Academy of Sciences of the United States of America|December 25, 2016
Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer's diseaseJohnny Habchi, Sean Chia, Ryan Limbocker, et al.
Nature Chemistry|May 9, 2018
Cholesterol catalyses Aβ42 aggregation through a heterogeneous nucleation pathway in the presence of lipid membranesJohnny Habchi, Sean Chia, Céline Galvagnion, et al.
Communications Biology|January 5, 2021
A dopamine metabolite stabilizes neurotoxic amyloid-β oligomersRodrigo Cataldi, Sean Chia, Katarina Pisani, et al.
Communications Biology|January 27, 2021
Publisher Correction: A dopamine metabolite stabilizes neurotoxic amyloid-β oligomersRodrigo Cataldi, Sean Chia, Katarina Pisani, et al.
ACS Nano|December 19, 2015
Microfluidic Diffusion Analysis of the Sizes and Interactions of Proteins under Native Solution ConditionsPaolo Arosio, Thomas Müller, Luke Rajah, et al.
Science Advances|March 3, 2016
An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Aβ42 aggregates linked with Alzheimer's diseaseJohnny Habchi, Paolo Arosio, Michele Perni, et al.
Nature Communications|August 17, 2024
α-Synuclein oligomers form by secondary nucleationCatherine K Xu, Georg Meisl, Ewa A Andrzejewska, et al.
Chemical Science|May 17, 2024
Molecular mechanism of α-synuclein aggregation on lipid membranes revealedAlexander J Dear, Xiangyu Teng, Sarah R Ball, et al.
Nature Structural & Molecular Biology|September 29, 2020
Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodiesSara Linse, Tom Scheidt, Katja Bernfur, et al.
Nature Communications|February 18, 2026
Structural defects in amyloid-β fibrils drive secondary nucleationJing Hu, Tom Scheidt, Dev Thacker, et al.
Pageof 29